US · JANX · BIOTECHNOLOGY
Janux Therapeutics, Inc. (JANX) intrinsic value and stock valuation
$10.08as of 2026-11-21 · Mkt cap 975.75M
Data updated · price as of 2026-11-21
- P/E
- Pro
- P/B
- Pro
- P/S
- Pro
Price history
Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.
Janux Therapeutics, Inc. DCF and intrinsic value
InvestorsCraft values JANX with the Chepakovich two-stage DCF model — currently rated fairly valued. How the model works · Run your own DCF prefilled from JANX’s statements →
Janux Therapeutics, Inc. Graham Number
The Graham Number is not defined for negative earnings or book value. Guide · Calculator →
How the business is doing
Fiscal 2019–2025, USD
Is it expensive?
Each multiple against its own 15-year range, or against peers where no history is available
Peers
Same-industry companies, ranked by market cap
Peer comparison
The peer comparison table is shown only to users with a Pro subscription.
Financials
Statements by fiscal year
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $10M | $10.6M | $8.08M | $8.61M | $3.64M |
| Operating income | -$-157.67M | -$-98.85M | -$-72.98M | -$-67.09M | -$-32.93M |
| Net income | -$-113.62M | -$-68.99M | -$-58.29M | -$-63.06M | -$-32.67M |
| EPSd | -$-1.83M | -$-1.28M | -$-1.32M | -$-1.52M | -$-792.19K |
| Operating cash flow | -$-82.23M | -$-43.81M | -$-50.58M | -$-42.92M | -$-16.98M |
| Capital expenditure | -$-1.04M | -$-360K | -$-1.85M | -$-6.45M | -$-1.48M |
| Free cash flow | -$-83.28M | -$-44.17M | -$-52.42M | -$-49.37M | -$-18.46M |
| Total assets | $1.01B | $1.06B | $380.4M | $364M | $379.8M |
| Total debt | $22.1M | $23M | $24.5M | $25.3M | $190K |
| Net debt | -$-30.2M | -$-407.58M | $5.34M | -$-26.12M | -$-35.39M |
| Total equity | $956.8M | $1.02B | $344.4M | $320.7M | $366.3M |
| Cash and short-term investments | $966.6M | $1.03B | $344M | $327M | $375M |
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $10M | $10.6M | $8.08M | $8.61M | $3.64M |
| Cost of revenue | $2.03M | $2.06M | $1.96M | $840K | $26.2M |
| Gross profit | $7.97M | $8.53M | $6.13M | $7.77M | -$-22.6M |
| Research and development expenses | $125.9M | $68.4M | $54.9M | $53.4M | $26.2M |
| Selling, general and administrative expenses | $41.8M | $41.1M | $26.1M | $22.3M | $10.3M |
| Other expenses | -$-2.03M | -$-2.06M | -$-1.96M | -$-840K | -$-26.24M |
| Operating expenses | $165.6M | $107.4M | $79.1M | $74.9M | $10.3M |
| Cost and expenses | $167.7M | $109.4M | $81.1M | $75.7M | $36.6M |
| Interest income | $44M | $29.9M | $14.7M | $4.03M | $260K |
| Interest expense | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Depreciation and amortization | $2.03M | $2.06M | $1.96M | $840K | $110K |
| Ebitda | -$-111.6M | -$-66.93M | -$-56.34M | -$-62.22M | -$-32.56M |
| Operating income | -$-157.67M | -$-98.85M | -$-72.98M | -$-67.09M | -$-32.93M |
| Total other income/expenses, net | $44M | $29.9M | $14.7M | $4.03M | $260K |
| Income before tax | -$-113.62M | -$-68.99M | -$-58.29M | -$-63.06M | -$-32.67M |
| Income tax expense | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net income | -$-113.62M | -$-68.99M | -$-58.29M | -$-63.06M | -$-32.67M |
| Weighted average shares outstanding | $62M | $53.8M | $44M | $41.5M | $41.2M |
| Weighted average diluted shares outstanding | $62M | $53.8M | $44M | $41.5M | $41.2M |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash and short-term investments | $966.6M | $1.03B | $344M | $327M | $375M |
| Net receivables | $6.43M | $5.38M | $2.16M | $700K | $200K |
| Inventory | $0.00 | $0.00 | $0.00 | -$-700K | $0.00 |
| Total current assets | $975.9M | $1.03B | $349.2M | $332.4M | $377M |
| Property, plant and equipment, net | $22.3M | $24.2M | $27.8M | $29.4M | $1.6M |
| Goodwill and intangible assets | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Long-term investments | $820K | $0.00 | $0.00 | $820K | $0.00 |
| Total non-current assets | $31.6M | $27.9M | $31.2M | $31.6M | $2.81M |
| Total assets | $1.01B | $1.06B | $380.4M | $364M | $379.8M |
| Accounts payable | $4.97M | $4.03M | $2.42M | $2.16M | $2.46M |
| Short-term debt | $2.39M | $1.75M | $1.52M | $760K | $190K |
| Deferred revenue | $0.00 | $0.00 | $1.71M | $5.41M | $5.16M |
| Total current liabilities | $25M | $17.5M | $13M | $16.5M | $12.8M |
| Long-term debt | $19.8M | $21.3M | $23M | $24.5M | $0.00 |
| Deferred revenue, non-current | $0.00 | $0.00 | $0.00 | $2.22M | $700K |
| Total non-current liabilities | $25.7M | $21.3M | $23M | $26.8M | $700K |
| Capital lease obligations | $19.8M | $23M | $24.5M | $25.3M | $190K |
| Total liabilities | $50.7M | $38.7M | $36.1M | $43.3M | $13.5M |
| Common stock | $60K | $60K | $50K | $40K | $40K |
| Retained earnings | -$-351.38M | -$-237.76M | -$-168.76M | -$-110.47M | -$-47.41M |
| Accumulated other comprehensive income (loss) | $4.32M | $2.16M | $670K | -$-1.53M | -$-270K |
| Total equity | $956.8M | $1.02B | $344.4M | $320.7M | $366.3M |
| Total investments | $914.2M | $594.6M | $324.8M | $275.6M | $339.4M |
| Total debt | $22.1M | $23M | $24.5M | $25.3M | $190K |
| Net debt | -$-30.2M | -$-407.58M | $5.34M | -$-26.12M | -$-35.39M |
Cash flow statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net income | -$-113.62M | -$-68.99M | -$-58.29M | -$-63.06M | -$-32.67M |
| Depreciation and amortization | $2.03M | $2.06M | $1.96M | $840K | $110K |
| Stock-based compensation | $40.2M | $33M | $20M | $17.2M | $6.91M |
| Change in working capital | $6.71M | $690K | -$-6.55M | $4.28M | $8.84M |
| Accounts receivable | $0.00 | $0.00 | $0.00 | $0.00 | $8M |
| Inventory | $0.00 | $0.00 | $0.00 | $0.00 | $830K |
| Accounts payable | $980K | $1.58M | $280K | -$-290K | $2.14M |
| Net cash provided by operating activities | -$-82.23M | -$-43.81M | -$-50.58M | -$-42.92M | -$-16.98M |
| Investments in property, plant and equipment | -$-1.04M | -$-360K | -$-1.85M | -$-6.45M | -$-1.48M |
| Acquisitions, net | $0.00 | $0.00 | $0.00 | -$-64.71M | $339.5M |
| Net cash used for investing activities | -$-300.98M | -$-258.02M | -$-41.19M | $58.3M | -$-340.96M |
| Common stock issued | $5.29M | $698.3M | $56.5M | $500K | $204.2M |
| Common stock repurchased | -$-350K | $0.00 | $0.00 | $0.00 | $0.00 |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net cash used for financing activities | $4.95M | $713.2M | $59.6M | $500K | $386.5M |
| Net change in cash | -$-378.27M | $411.4M | -$-32.22M | $15.8M | $28.6M |
| Cash at end of period | $53.2M | $431.4M | $20M | $52.2M | $36.4M |
| Operating cash flow | -$-82.23M | -$-43.81M | -$-50.58M | -$-42.92M | -$-16.98M |
| Capital expenditure | -$-1.04M | -$-360K | -$-1.85M | -$-6.45M | -$-1.48M |
| Free cash flow | -$-83.28M | -$-44.17M | -$-52.42M | -$-49.37M | -$-18.46M |
Line items
Line items
Line items
About Janux Therapeutics, Inc.
Janux Therapeutics, Inc. is a biopharmaceutical company dedicated to developing innovative cancer therapies. The firm leverages its proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to create treatments designed to activate the body's T cells to fight tumors. Currently, Janux has several promising TRACTr product candidates in their early preclinical or discovery stages, which are engineered to target specific antigens such as prostate-specific membrane antigen, epidermal growth factor receptor, and trophoblast cell surface antigen 2. In addition to its TRACTr pipeline, the company is also developing a Tumor Activated Immunomodulator (TRACIr) — a costimulatory bispecific candidate designed to enhance T cell anti-tumor activity by engaging with programmed death-ligand 1 and CD28. Furthermore, a specific focus for their EGFR-TRACTr program is addressing epidermal growth factor receptor, a target prevalent in many cancer types and already a focus of numerous approved monoclonal antibody treatments. Janux Therapeutics, Inc. was founded in 2017 and is headquartered in La Jolla, California.
- CEO
- David Alan Campbell
- Employees
- 109
- Beta
- 2.51
Explore
Frequently asked questions
What is the intrinsic value of Janux Therapeutics, Inc. (JANX)?
Janux Therapeutics, Inc. (JANX) is currently fairly valued based on the InvestorsCraft IC model — IC value is within 20% of the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.
Is JANX undervalued?
JANX trades at a price of $10.08 (Nov 21, 2026): fairly valued — IC value is within 20% of the price.
How is the intrinsic value calculated?
InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.
How often is this page updated?
Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.